Skip to content

Journal · Biotechnology · Updated 21 November 2026

Biotechnology Letters

Read Biotechnology Letters articles on DeepDyve. No university library needed.

Biotechnology Letters has published since 1979 and covers results from across biotechnology, from enzyme catalysis and microalgal biofuels to recombinant protein production, veterinary vaccines and probiotic bacteria. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Biotechnology Letters
Journal cover

Biotechnology Letters at a glance

Full title
Biotechnology Letters
Abbreviation (NLM)
Biotechnol Lett
Publisher
Springer Nature
Print ISSN
0141-5492
Online ISSN (eISSN)
1573-6776
First published
1979
Subjects
Biotechnology
Access model
Hybrid (11% free to read in 2026)

Ways to access Biotechnology Letters

11% of the articles Biotechnology Letters published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 11% of Biotechnology Letters articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Biotechnology Letters. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Biotechnology Letters articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Biotechnology Letters’ 2025 Journal Impact Factor is 2.5, and its 5-year Impact Factor is 2.6.

2.5

Journal Impact Factor (2025)

2.6

5-year Impact Factor (2025)

18 days

Median time to first decision

Source: journal metrics on the Biotechnology Letters homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Biotechnology Letters research worth reading

Published January to May 2026. Summaries describe what the authors report.

  1. LitStreamCancer therapy · RNA therapeutics

    Antisense oligonucleotides: targeting oncogenic long non-coding RNAs for cancer therapy

    In a narrative review of preclinical studies, Irandoost and colleagues report that antisense oligonucleotides targeting oncogenic long non-coding RNAs such as MALAT1, PVT1 and NEAT1 suppress tumor growth, invasion, metastasis and chemoresistance, and say well-structured clinical trials are still required.

    Irandoost et al. · Biotechnology Letters, published online March 14, 2026 · DOI 10.1007/s10529-026-03713-9

  2. LitStreamEnzyme immobilization · Nanomaterials

    Preparation, characterization, and enzymatic properties of laccase immobilized on MnO2 nanoparticles via adsorption method

    Yue and colleagues report that laccase immobilized on sheet-shaped δ-MnO2 had an optimal temperature of 75 °C and optimal pH of 3, was more stable than free laccase, and kept 74.51% relative activity after 30 days of storage at −4 °C.

    Yue et al. · Biotechnology Letters, published online January 21, 2026 · DOI 10.1007/s10529-026-03694-9

  3. LitStreamFermentation · Plant growth regulators

    Enhanced gibberellic acid production in Fusarium fujikuroi through ARTP-EMS mutagenesis and fermentation optimization

    Wang and colleagues report that a high-yield Fusarium fujikuroi mutant generated by ARTP and EMS mutagenesis reached a gibberellic acid titer of 2.483 g/L in a 5-L bioreactor, a 33.38% increase over the parent strain.

    Wang et al. · Biotechnology Letters, published online March 2, 2026 · DOI 10.1007/s10529-026-03699-4

  4. Open accessBiocatalysis · Enzymes

    Oligosaccharide oxidase for the enzymatic synthesis of glucosaminic acids

    The authors show that the fungal chito-oligosaccharide oxidase LbChi7A converted at least 90% of d-glucosamine to d-glucosaminic acid and 100% of N-acetyl-d-glucosamine to its acid within 60 min, with no inhibition by hydrogen peroxide even at 860 mM.

    Raji et al. · Biotechnology Letters, published online March 17, 2026 · DOI 10.1007/s10529-026-03721-9

  5. LitStreamExosomes · Cancer

    Exosomes-mediated intercellular communication and their theragnostic potential against cancer and related disorders: a comprehensive review

    Sarkar and colleagues review exosomes, extracellular vesicles of 30 to 150 nm that mediate communication between cells, covering isolation and detection methods, their roles in cancer as biomarkers and drug carriers, and hurdles such as large-scale manufacturing consistency and regulation.

    Sarkar et al. · Biotechnology Letters, published online May 9, 2026 · DOI 10.1007/s10529-026-03738-0

See every Biotechnology Letters article on DeepDyve

Questions about Biotechnology Letters

How can I read Biotechnology Letters articles without a subscription?

11% of Biotechnology Letters articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Biotechnology Letters articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Biotechnology Letters?

Biotechnology Letters’ NLM (PubMed) abbreviation is Biotechnol Lett.

What is the ISSN of Biotechnology Letters?

The print ISSN is 0141-5492 and the online ISSN is 1573-6776.

What is the impact factor of Biotechnology Letters?

Biotechnology Letters’ Journal Impact Factor is 2.5 (2025), and its 5-year Impact Factor is 2.6, according to Springer Nature’s published metrics.

Is Biotechnology Letters open access?

Biotechnology Letters is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 13 of 114 Biotechnology Letters articles (11%) carry a Creative Commons license, per Crossref.

Biotechnology Letters articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Biotechnology Letters today

One month free, then less than $2 a day. Biotechnology Letters, plus millions of articles from thousands of journals.

Start free month

Like this: